After the Bell
Before the Bell
Jim Cramer's Daily Booyah
Winners & Losers
Illumina fell 24% on news that it was cutting revenue guidance.
Vertex Pharmaceuticals shares are down 31% year to date. Investors are wondering if they should hang on, buy or wait.
The company also could look to acquire a smaller biotech company, though likely not Medivation.
It might be best to make this a late-afternoon purchase.
©1996-2016 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.